Evolution Therapeutics has been recognised by the Biotechnology and Biosciences Research Council (BBSRC) in their 2023 impact showcase. This showcase serves as a compilation of impact stories stemming from BBSRC investments, shedding light on significant outcomes resulting from their support of cutting-edge research and highlights the role of outstanding organisations and individuals leading the crucial work to address key strategic global challenges.
Back in 2022, Dr. James Gavin and Professor Andrew Devitt successfully secured a spot on the BBSRC Innovation to Commercialisation of University Research (ICURe) programme, an initiative which trains, funds, and supports research teams to assess the market viability of products or services rooted in bioscience-based concepts, research, and technologies. Their participation enabled them to commercially apply their research in bioengineered extracellular vesicles, ultimately leading to establishing the spin-out company, EVolution Therapeutics.
Watch the video to hear from the founding members delve into the scientific intricacies of EVolution Therapeutic’s groundbreaking therapeutic approach for non-healing wounds and discuss the invaluable support and opportunities provided by BBSRC, which have been essential in propelling the company’s research and commercialisation efforts forward.
The full BBSRC impact showcase 2023 is available to view here.